-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MAI Capital Management Sells 3,385 Shares of Roche Holding AG (OTCMKTS:RHHBY)
MAI Capital Management Sells 3,385 Shares of Roche Holding AG (OTCMKTS:RHHBY)
MAI Capital Management reduced its position in shares of Roche Holding AG (OTCMKTS:RHHBY – Get Rating) by 19.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,332 shares of the company's stock after selling 3,385 shares during the quarter. MAI Capital Management's holdings in Roche were worth $598,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of RHHBY. Sofinnova Investments Inc. acquired a new stake in shares of Roche during the 4th quarter worth about $70,764,000. Fisher Asset Management LLC lifted its position in Roche by 25.0% during the first quarter. Fisher Asset Management LLC now owns 5,823,906 shares of the company's stock worth $289,890,000 after acquiring an additional 1,165,391 shares during the last quarter. Cardinal Capital Management Inc. bought a new stake in shares of Roche during the first quarter worth approximately $18,402,000. Cullen Capital Management LLC grew its position in shares of Roche by 11.8% in the first quarter. Cullen Capital Management LLC now owns 1,144,467 shares of the company's stock valued at $56,548,000 after purchasing an additional 120,595 shares during the last quarter. Finally, Kempner Capital Management Inc. bought a new position in shares of Roche during the first quarter worth approximately $3,625,000. Institutional investors own 0.23% of the company's stock.
Get Roche alerts:Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on RHHBY shares. Cowen dropped their target price on Roche from $58.00 to $48.00 and set an "outperform" rating for the company in a report on Monday, June 27th. Jefferies Financial Group raised shares of Roche from a "hold" rating to a "buy" rating in a report on Thursday, September 8th. Deutsche Bank Aktiengesellschaft reduced their price target on Roche from CHF 350 to CHF 325 and set a "hold" rating on the stock in a research report on Friday, July 22nd. Cowen cut their target price on Roche from $58.00 to $48.00 and set an "outperform" rating for the company in a research report on Monday, June 27th. Finally, Credit Suisse Group upgraded Roche from a "neutral" rating to an "outperform" rating in a research report on Thursday, September 15th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $260.14.
Roche Price Performance
RHHBY opened at $40.62 on Friday. The company's 50 day moving average is $41.30 and its 200-day moving average is $43.42. Roche Holding AG has a 1-year low of $37.88 and a 1-year high of $53.86. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.73 and a current ratio of 0.93.Roche Profile
(Get Rating)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
Featured Stories
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
MAI Capital Management reduced its position in shares of Roche Holding AG (OTCMKTS:RHHBY – Get Rating) by 19.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,332 shares of the company's stock after selling 3,385 shares during the quarter. MAI Capital Management's holdings in Roche were worth $598,000 at the end of the most recent reporting period.
Mai Capital Management根據其提交給美國證券交易委員會的最新Form 13F文件,在第二季度將其在羅氏控股公司(OTCMKTS:RHHBY-GET Rating)的股票頭寸減少了19.1%。該機構投資者在本季度出售了3385股後,持有該公司14,332股股票。在最近一次報告期結束時,Mai Capital Management持有的羅氏股份價值59.8萬美元。
A number of other hedge funds and other institutional investors have also bought and sold shares of RHHBY. Sofinnova Investments Inc. acquired a new stake in shares of Roche during the 4th quarter worth about $70,764,000. Fisher Asset Management LLC lifted its position in Roche by 25.0% during the first quarter. Fisher Asset Management LLC now owns 5,823,906 shares of the company's stock worth $289,890,000 after acquiring an additional 1,165,391 shares during the last quarter. Cardinal Capital Management Inc. bought a new stake in shares of Roche during the first quarter worth approximately $18,402,000. Cullen Capital Management LLC grew its position in shares of Roche by 11.8% in the first quarter. Cullen Capital Management LLC now owns 1,144,467 shares of the company's stock valued at $56,548,000 after purchasing an additional 120,595 shares during the last quarter. Finally, Kempner Capital Management Inc. bought a new position in shares of Roche during the first quarter worth approximately $3,625,000. Institutional investors own 0.23% of the company's stock.
許多其他對衝基金和其他機構投資者也買賣了RHHBY的股票。Sofinnova Investments Inc.在第四季度收購了價值約70,764,000美元的羅氏新股。Fisher Asset Management LLC在第一季度將其在羅氏的頭寸提高了25.0%。Fisher Asset Management LLC現在擁有5823,906股該公司股票,價值289,890,000美元,在上個季度額外收購了1,165,391股。Cardinal Capital Management Inc.在第一季度購買了價值約18,402,000美元的羅氏新股。第一季度,Cullen Capital Management LLC在羅氏股票中的頭寸增加了11.8%。庫倫資本管理有限責任公司在上個季度購買了120,595股後,現在擁有1,144,467股該公司的股票,價值56,548,000美元。最後,肯普納資本管理公司在第一季度購買了價值約3,625,000美元的羅氏新股票頭寸。機構投資者持有該公司0.23%的股票。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities research analysts have recently weighed in on RHHBY shares. Cowen dropped their target price on Roche from $58.00 to $48.00 and set an "outperform" rating for the company in a report on Monday, June 27th. Jefferies Financial Group raised shares of Roche from a "hold" rating to a "buy" rating in a report on Thursday, September 8th. Deutsche Bank Aktiengesellschaft reduced their price target on Roche from CHF 350 to CHF 325 and set a "hold" rating on the stock in a research report on Friday, July 22nd. Cowen cut their target price on Roche from $58.00 to $48.00 and set an "outperform" rating for the company in a research report on Monday, June 27th. Finally, Credit Suisse Group upgraded Roche from a "neutral" rating to an "outperform" rating in a research report on Thursday, September 15th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $260.14.
許多股票研究分析師最近紛紛買入RHHBY的股票。考恩在6月27日週一的一份報告中將羅氏的目標價從58.00美元下調至48.00美元,併為該公司設定了“跑贏大盤”的評級。在9月8日星期四的一份報告中,傑富瑞金融集團將羅氏的股票評級從持有上調至買入。德意志銀行Aktiengesellschaft在7月22日(星期五)的一份研究報告中將羅氏的目標價從350瑞士法郎下調至325瑞士法郎,並對該股設定了“持有”評級。考恩在6月27日週一的一份研究報告中將羅氏的目標價從58.00美元下調至48.00美元,併為該公司設定了“跑贏大盤”的評級.最後,瑞士信貸集團在9月15日週四的一份研究報告中,將羅氏的評級從中性上調至表現優於大盤。一名分析師對該股的評級為賣出,三名分析師給出了持有評級,八名分析師給出了該公司股票的買入評級。根據MarketBeat的數據,該公司的平均評級為“中等買入”,平均目標價為260.14美元。
Roche Price Performance
羅氏的價格表現
Roche Profile
羅氏簡介
(Get Rating)
(獲取評級)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
羅氏控股公司在瑞士、德國、美國、奧地利、荷蘭、英國、法國、比利時和國際上從事製藥和診斷業務。該公司提供治療腫瘤學、神經科學、感染學、免疫學、心血管和新陳代謝、眼科和呼吸系統以及貧血、癌症、皮膚科、血友病、炎症和自身免疫、神經科和移植的藥物。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免費獲取StockNews.com關於羅氏的研究報告(RHHBY)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 雷神工業走出谷底
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
接受《羅氏日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對羅氏和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧